GSK Projects Oncology Pipeline to Nearly Double in 2025
GSK says its clinical-stage oncology portfolio, currently around 15 assets alongside five approved cancer drugs, is set to nearly double next year. The company attributes the expansion to a recent series of acquisitions and licensing deals.
GoKawiil's interpretation of the reporting above, not reported fact.
A sharply larger pipeline could reshape GSK's revenue mix as it seeks to reduce reliance on older drug categories, though early-stage assets carry high attrition risk before reaching market. The scale of the buildout suggests GSK is betting heavily on oncology as a growth driver, a strategy investors will likely scrutinize for returns on its dealmaking spend.
- GSK currently has five approved cancer medicines and about 15 clinical-stage assets.
- The company expects its oncology pipeline to nearly double by next year.
- Growth is driven by a recent spree of acquisitions and licensing deals.
Source: wsj.com, 2026-10-27
Published there as: “GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.